Cargando…

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection

Despite the success of COVID-19 vaccines in preventing infection and/or severe disease, there has been an increase in SARS-CoV-2 infections in vaccinated individuals owing to the waning vaccine-derived immunity, and the emergence of new variants which encode escape mutations in Spike. Following brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seow, Jeffrey, Shalim, Zayed A., Graham, Carl, Kimuda, Simon, Pillai, Aswin, Lechmere, Thomas, Kurshan, Ashwini, Khimji, Atika M., Snell, Luke B., Nebbia, Gaia, Mant, Christine, Waters, Anele, Fox, Julie, Malim, Michael H., Doores, Katie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653880/ https://www.ncbi.nlm.nih.gov/pubmed/37747187 http://dx.doi.org/10.1128/mbio.01206-23

Ejemplares similares

Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
por: Lechmere, Thomas, et al.
Publicado: (2022)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
por: Seow, Jeffrey, et al.
Publicado: (2022)

Endogenous antibody responses in REGN-COV2-treated SARS-CoV-2-infected individuals
por: Kurshan, Ashwini, et al.
Publicado: (2023)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders
por: Harrington, Patrick, et al.
Publicado: (2022)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

Emergence of Omicron BA.1 and BA.2 variants and concern over vaccine breakthrough infection
por: Sukaina, Mahnoor, et al.
Publicado: (2022)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients
por: Harrington, Patrick, et al.
Publicado: (2021)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Evolution of antibody immunity following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2023)

Author Correction: Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Breakthrough in the high-pressure structures of Ba based on full exploitation of aperiodic symmetry
por: Boldyreva, Elena V.
Publicado: (2017)

Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
por: Yang, Jinyoung, et al.
Publicado: (2023)

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

Strategic execution: driving breakthrough performance in business
por: Carrig, Kenneth J, et al.
Publicado: (2019)

Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
por: McKenzie, Duncan R., et al.
Publicado: (2022)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines
por: Bowen, John E., et al.
Publicado: (2022)

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2021)

Contrasting Modes of New World Arenavirus Neutralization by Immunization-Elicited Monoclonal Antibodies
por: Ng, Weng M., et al.
Publicado: (2022)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection
por: Cheng, Samuel SM, et al.
Publicado: (2022)

COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022)

SARS‐CoV‐2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID‐19 due to Omicron BA.1 and BA.2
por: de Michelena, Paula, et al.
Publicado: (2022)

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
por: Dupont, Liane, et al.
Publicado: (2021)

Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections
por: Dupont, Liane, et al.
Publicado: (2021)

BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies
por: Singh, Janmejay, et al.
Publicado: (2023)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection
por: Yao, Lin, et al.
Publicado: (2022)

Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies
por: Zhou, Hao, et al.
Publicado: (2022)

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
por: Harrington, Patrick, et al.
Publicado: (2021)

Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients
por: Platen, Louise, et al.
Publicado: (2023)

SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r8lkms82roospu64psfgldaihm